People who use or are considering Ozempic (semaglutide) often seek clarity about pregnancy risks, labeled warnings, and what to do if they are pregnant or planning pregnancy. Ozempic is a GLP-1 receptor agonist prescribed for type 2 diabetes and chronic weight management in adults, and questions about safety during conception and pregnancy are common. This overview summarizes labeled information, clinical considerations, and practical steps, with an emphasis on evidence-based context that remains useful over time. If you are pregnant, think you may be pregnant, or are planning pregnancy, work with the healthcare provider who manages your diabetes or weight care to review benefits, risks, and alternatives specific to your health needs.
What Ozempic Is and How It Works
Ozempic is a once-weekly injectable prescription medicine containing semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It is approved to improve glycemic control in adults with type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. It is also prescribed at higher doses under the brand name Wegovy for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Class-wide, GLP-1 receptor agonists carry a Pregnancy Category X designation under the former FDA letter-based system, and the current Pregnancy and Lactation Labeling Rule requires specific Pregnancy, Lactation, and Females and Males Reproductive Potential sections. Understanding this context is important when evaluating pregnancy-related concerns.
Labeled Pregnancy Warning and Risk Considerations
The current product label for Ozempic contains a boxed warning highlighting animal reproduction studies that observed harm to the developing fetus at doses that produced maternal exposure. These findings raise concerns about potential risks to human pregnancies, although animal study results do not always predict human outcomes. The label advises people who are pregnant or who become pregnant while using Ozempic to immediately contact their healthcare provider. Because semaglutide may affect fetal development, the general recommendation is to avoid use during pregnancy and to discontinue as advised by a clinician who can weigh maternal benefit against potential fetal risk.
Key Label Points (Ozempic)
| Attribute | Verified Detail | Source Type |
|---|---|---|
| Drug Class | GLP-1 Receptor Agonist | Label Information |
| Pregnancy Category (legacy) | Category X | Former FDA Classification |
| Current Label Section | Pregnancy and Lactation Labeling Rule Sections | Prescribing Information |
| Animal Reproduction Findings | Observed Fetal Harm at Maternal Exposure Levels | Preclinical Toxicology Data |
| Human Data | Limited; Based on Animal Studies and Clinical Experience | Label and Case Reports |
Potential Risks During Pregnancy
In pregnancy, maintaining glycemic control is important for both maternal and fetal health. However, the use of Ozempic during pregnancy is not recommended based on available animal data and the potential for fetal harm. Possible concerns related to GLP-1 receptor agonist exposure in early pregnancy include theoretical risks to organ development, while later exposures may affect fetal growth and metabolism. Because human data are limited, clinicians typically rely on labeled warnings and expert guidance when counseling people who are pregnant or who become pregnant while using Ozempic. Decisions about continuation or discontinuation should be made in partnership with a healthcare provider who can assess maternal clinical status and discuss appropriate alternatives.
Pregnancy Considerations Quick Reference
- Ozempic is not recommended during pregnancy based on animal study findings.
- Contact your healthcare provider immediately if you are pregnant or become pregnant while using Ozempic.
- Glycemic control is important in pregnancy; discuss evidence-based alternatives with your clinician.
- Do not stop or change medication without medical guidance, as abrupt changes can affect blood sugar control.
- Report any pregnancy exposure to your healthcare provider for individualized risk assessment and follow-up.
Pregnancy Planning and Contraception
For people who are planning pregnancy, discussions with a healthcare provider about diabetes or weight management goals can help align treatment with reproductive plans. Because Ozempic may affect fertility or be harmful during pregnancy, clinicians may recommend effective contraception while using the medication and may adjust therapy before conception. Considering future pregnancy timing allows for medication review and optimization to support a healthier pregnancy and improve outcomes. This planning also supports informed decision-making about alternative therapies that may be safer during the preconception period.
Reproductive Planning Points
- Discuss family planning with your clinician if you use Ozempic.
- Use reliable contraception while using Ozempic if pregnancy is not intended.
- Plan medication reviews before attempting pregnancy when possible.
- Explore alternative treatments that may be safer during pregnancy with your provider.
- Seek early prenatal care if you become pregnant after discontinuing Ozempic.
Use During Lactation and Breastfeeding
It is not known whether semaglutide is present in human milk or whether it affects breastfed infants. Because many medications can pass into breast milk and potential adverse reactions cannot be ruled out, caution is advised. People who are breastfeeding or who plan to breastfeed should discuss risks and benefits with their healthcare provider to determine whether to continue breastfeeding, discontinue nursing, or discontinue the medication. Individual decisions should consider the importance of the medication for the parent’s health and the benefits of breastfeeding for the infant.
When to Contact a Healthcare Provider
People using Ozempic who suspect they may be pregnant, experience symptoms of pregnancy, or are actively trying to conceive should contact their healthcare provider promptly. Early discussion supports timely assessment of pregnancy status, review of treatment options, and coordination of care with obstetric or diabetes specialists if needed. Anyone who becomes pregnant while taking Ozempic should be reported to the provider and, if recommended, to pregnancy registries that monitor outcomes associated with GLP-1 receptor agonist exposure during pregnancy.
Summary
Ozempic is not recommended during pregnancy based on animal study findings of fetal harm and limited human data. The current label includes a boxed warning and advises people who are pregnant or who become pregnant to contact their healthcare provider immediately. For people planning pregnancy, using effective contraception and discussing treatment plans with a clinician can help align diabetes or weight management with reproductive goals. Because decisions about medication use in pregnancy are individual, personalized guidance from a healthcare provider is essential. This relationship-focused guidance is intended to be durable and useful as understanding of GLP-1 receptor agonists in pregnancy continues to evolve.